Showing 351-360 of 7598 results for "".
Using Fillers in the Nose
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/using-fillers-in-the-nose/19204/Steven Dayan, MD, talks about the use of fillers in the nose for temporary cosmetic improvement or to tweak surgical outcomes.DermWire TV: Factors Affecting Long-term Antibiotic Prescriptions for Acne; Biologics Firm Focusing on Plaque Psoriasis Makes an Important Acquisition; Practical Dermatology Launches Two New Video Series
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-factors-affecting-long-term-antibiotic-prescriptions-acne-biologics-firm-focusing-plaque-psoriasis-makes-important-acquisition-practical-dermatology-launches-two-new-video-series/24319/In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a major acquisition; and Practical Dermatology® launches two new video series focusing on advancing treatment and improving uVitiligo: Current and Future Developments
https://practicaldermatology.com/conferences/maui-derm-2020/vitiligo-current-and-future-developments/19722/John E. Harris, MD, PhD reviews treatment advances and emerging science in vitiligo. From new topical agents to intriguing studies on a potential role for biologics, there is very good reason to be optimistic about the future of vitiligo treatment.The First 5 Minutes with a Patient
https://practicaldermatology.com/series/pa-perspectives/first-5-minutes-patient/27105/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses the importance of crafting the right message during the first 5 minutes with a patient.DermWireTV: USPS Task Force Skin Cancer Screening Update; The 4th Annual San Diego Dermatology Symposium; Upcoming National Botox Day, Plus More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-usps-task-force-skin-cancer-screening-update-the-4th-annual-san-diego-dermatology-symposium-upcoming-national-botox-day-plus-more/20155/The United States Preventive Services Task Force says more research is needed before recommending screening for skin cancer in people without symptoms, an update on the Fourth Annual San Diego Dermatology Symposium, plus more top news in this episode of DermWireTV.Journal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAAFirst Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingHow Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiFirst, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.How Incyte Is Following the Science to Develop Innovative Solutions for Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/atopic-dermatitis/how-incyte-is-following-the-science-to-develop-innovative-solutions-for-immune-mediated-skin-conditions/20158/Jim Lee, head of the Inflammation and Autoimmunity clinical development group at Incyte, discusses the role of the immune system in atopic dermatitis (AD) and vitiligo and shares how Incyte is following the science to develop innovative options impacting the lives of people with these conditions.